Literature DB >> 16753269

Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern.

T Melnikova1, A Savonenko, Q Wang, X Liang, T Hand, L Wu, W E Kaufmann, A Vehmas, K I Andreasson.   

Abstract

Administration of non-steroidal anti-inflammatory agents reduces the risk of developing Alzheimer's disease in normal aging populations, an effect that may occur from inhibition of the cyclooxygenases, the rate-limiting enzymes in the formation of prostaglandins. In this study, we investigated whether increased activity of cyclooxygenase-2 (COX-2), the inducible isoform of cyclooxygenase, potentiates disease progression in a transgenic mouse model of Alzheimer's disease. To study the functional effects of COX-2 activity, male and female bigenic mice (amyloid precursor protein with Swedish mutation [APPswe]-presenilin-1 protein with deletion of exon 9 [PS1dE9] and trigenic COX-2/APPswe-PS1dE9) were behaviorally tested +/-administration of the selective COX-2 inhibitor celecoxib. Behavioral testing included a three-trial Y maze that measures spatial working and recognition memories and an open field task that tested levels of hyperactivity. Overexpression of COX-2 in APPswe-PS1dE9 mice resulted in specific deficits in spatial working memory in female but not male mice. These sex-specific deficits were abolished by pharmacological inhibition of COX-2 activity. Importantly, COX-2-associated deficits were dependent on co-expression of all three transgenes since COX-2 single transgenic and APPswe-PS1dE9 bigenic mice showed normal memory. Quantification of amyloid plaque load and total Abeta 40 and 42 peptides did not reveal significant differences in trigenic versus bigenic mice treated with either vehicle or celecoxib. Taken together, these data indicate an interaction between the effects of COX-2 and Abeta peptides on cognition that occurs in a sex-specific manner in the absence of significant changes in amyloid burden. These findings suggest that pathological activation of COX-2 may potentiate the toxicity of Abeta peptides, particularly in females, without significantly affecting Abeta accumulation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16753269     DOI: 10.1016/j.neuroscience.2006.05.001

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  49 in total

Review 1.  Streptozotocin Intracerebroventricular-Induced Neurotoxicity and Brain Insulin Resistance: a Therapeutic Intervention for Treatment of Sporadic Alzheimer's Disease (sAD)-Like Pathology.

Authors:  Pradip K Kamat; Anuradha Kalani; Shivika Rai; Santosh Kumar Tota; Ashok Kumar; Abdullah S Ahmad
Journal:  Mol Neurobiol       Date:  2015-08-23       Impact factor: 5.590

Review 2.  Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature.

Authors:  Tony Wyss-Coray; Joseph Rogers
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

Review 3.  Protein synthesis inhibitors, gene superinduction and memory: too little or too much protein?

Authors:  Jelena Radulovic; Natalie C Tronson
Journal:  Neurobiol Learn Mem       Date:  2007-09-29       Impact factor: 2.877

4.  Nonsteroidal anti-inflammatory drug, indomethacin improves spatial memory and NMDA receptor function in aged animals.

Authors:  Ashok Kumar; Asha Rani; Rachel B Scheinert; Brandi K Ormerod; Thomas C Foster
Journal:  Neurobiol Aging       Date:  2018-06-28       Impact factor: 4.673

5.  Prostaglandin signaling suppresses beneficial microglial function in Alzheimer's disease models.

Authors:  Jenny U Johansson; Nathaniel S Woodling; Qian Wang; Maharshi Panchal; Xibin Liang; Angel Trueba-Saiz; Holden D Brown; Siddhita D Mhatre; Taylor Loui; Katrin I Andreasson
Journal:  J Clin Invest       Date:  2014-12-08       Impact factor: 14.808

6.  Sex-related dimorphism in dentate gyrus atrophy and behavioral phenotypes in an inducible tTa:APPsi transgenic model of Alzheimer's disease.

Authors:  Tatiana Melnikova; DaMin Park; Lauren Becker; Deidre Lee; Eugenia Cho; Nuzhat Sayyida; Jing Tian; Karen Bandeen-Roche; David R Borchelt; Alena V Savonenko
Journal:  Neurobiol Dis       Date:  2016-08-26       Impact factor: 5.996

7.  Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer's disease model mice.

Authors:  Nathaniel S Woodling; Damien Colas; Qian Wang; Paras Minhas; Maharshi Panchal; Xibin Liang; Siddhita D Mhatre; Holden Brown; Novie Ko; Irene Zagol-Ikapitte; Marieke van der Hart; Taline V Khroyan; Bayarsaikhan Chuluun; Prachi G Priyam; Ginger L Milne; Arash Rassoulpour; Olivier Boutaud; Amy B Manning-Boğ; H Craig Heller; Katrin I Andreasson
Journal:  Brain       Date:  2016-05-13       Impact factor: 13.501

8.  A role for cyclooxygenase-1 in beta-amyloid-induced neuroinflammation.

Authors:  Eduardo Candelario-Jalil
Journal:  Aging (Albany NY)       Date:  2009-04-13       Impact factor: 5.682

9.  Reversible pathologic and cognitive phenotypes in an inducible model of Alzheimer-amyloidosis.

Authors:  Tatiana Melnikova; Susan Fromholt; HyunSu Kim; Deidre Lee; Guilian Xu; Ashleigh Price; Brenda D Moore; Todd E Golde; Kevin M Felsenstein; Alena Savonenko; David R Borchelt
Journal:  J Neurosci       Date:  2013-02-27       Impact factor: 6.167

10.  Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity.

Authors:  Linda A Kotilinek; Marcus A Westerman; Qinwen Wang; Kimberly Panizzon; Giselle P Lim; Agnes Simonyi; Sylvain Lesne; Agnieszka Falinska; Linda H Younkin; Steven G Younkin; Michael Rowan; James Cleary; Roi Ann Wallis; Grace Y Sun; Greg Cole; Sally Frautschy; Roger Anwyl; Karen H Ashe
Journal:  Brain       Date:  2008-03       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.